layout image layout image
 
Diabetic Cooking header image

Diabetes Mellitus Links


Sleep less than 6 hours ups diabetes risk

European scientists identify a gene network that predisposes to type 1 diabetes

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Advinus discovers novel molecule for treatment of diabetes, completes Phase 1 Single Ascending Dose study

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET

<< 1 2 3 >>


 

Diabetic Cooking Recommended Products
Diabetes Mellitus News

Sleep less than 6 hours ups diabetes risk

WARWICK, England, Sept. 9 (UPI) -- People who sleep less than 6 hours a night aren't able to regulate glucose efficiently, increasing the risk of heart disease, British and U.S. researchers say. Heart disease - Diabetes mellitus - Health - Conditions and Diseases - United States

Read more...


European scientists identify a gene network that predisposes to type 1 diabetes

Type 1 diabetes is a metabolic disorder characterized by high blood sugar levels because the insulin-producing pancreatic beta cells are attacked and destroyed by the body's immune system.

Read more...


Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET (bromocriptine mesylate) tablets in the U.S.

Read more...


Advinus discovers novel molecule for treatment of diabetes, completes Phase 1 Single Ascending Dose study

Advinus Therapeutics, the research-based pharmaceutical company promoted by the TATA Group has discovered a novel molecule for the treatment of type II diabetes - GKM -001. The molecule is an activator of glucokinase; an enzyme that regulates glucose balance and insulin secretion in the body.

Read more...


Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET

SAN DIEGO & BRISTOL, Tenn. & TIVERTON, R.I.--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS), S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET® (bromocriptine mesylate) tablets in the U.S. CYCLOSET is a prescription drug approved by the U.S. Food ...

Read more...


 
layout image layout image